{"groups":[{"description":"Intravesical administration of ADSTILADRIN into the bladder","id":"FG000","title":"ADSTILADRIN"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"26"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Withdrawal of Consent"},{"reasons":[{"groupId":"FG000","numSubjects":"11"}],"type":"Other: not due to lack of tolerability"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"157"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"95"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"62"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Patients enrolled in the study who had at entry, confirmed by a pathology report: CIS only or Ta/T1 high- grade disease with concomitant CIS, or Ta/T1 high-grade disease without concomitant CIS and were \"BCG unresponsive\" which referred to patients with high-grade NMIBC who were unlikely to benefit from and who did not receive further intravesical BCG."}